- Home
- BROG vs IVA Comparison
BROG vs IVA Comparison
Compare BROG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- IVA
- Stock Information
- Founded
- BROG 2019
- IVA 2011
- Country
- BROG United Arab Emirates
- IVA France
- Employees
- BROG N/A
- IVA N/A
- Industry
- BROG Integrated oil Companies
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- IVA Health Care
- Exchange
- BROG Nasdaq
- IVA Nasdaq
- Market Cap
- BROG 114.0M
- IVA 117.3M
- IPO Year
- BROG N/A
- IVA 2020
- Fundamental
- Price
- BROG $1.26
- IVA $2.51
- Analyst Decision
- BROG
- IVA Strong Buy
- Analyst Count
- BROG 0
- IVA 4
- Target Price
- BROG N/A
- IVA $14.00
- AVG Volume (30 Days)
- BROG 20.5K
- IVA 28.6K
- Earning Date
- BROG 11-29-2024
- IVA 09-25-2024
- Dividend Yield
- BROG N/A
- IVA N/A
- EPS Growth
- BROG N/A
- IVA N/A
- EPS
- BROG N/A
- IVA N/A
- Revenue
- BROG $105,695,648.00
- IVA $20,652,523.00
- Revenue This Year
- BROG N/A
- IVA N/A
- Revenue Next Year
- BROG N/A
- IVA $361.78
- P/E Ratio
- BROG N/A
- IVA N/A
- Revenue Growth
- BROG 29.62
- IVA N/A
- 52 Week Low
- BROG $0.80
- IVA $1.53
- 52 Week High
- BROG $6.66
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- BROG 39.41
- IVA 45.32
- Support Level
- BROG $1.33
- IVA $2.52
- Resistance Level
- BROG $1.47
- IVA $2.77
- Average True Range (ATR)
- BROG 0.17
- IVA 0.13
- MACD
- BROG -0.04
- IVA -0.03
- Stochastic Oscillator
- BROG 14.17
- IVA 0.00
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.